No Data
GAUSH MEDITECH (02407.HK): The corneal confocal microscope has obtained the national medical instrument registration certificate.
On April 9, Gelonghui reported that GAUSH MEDITECH (02407.HK) announced that its wholly-owned subsidiary, GAUSH Innovation Technology Co., Ltd. ("GAUSH Innovation"), has independently developed the T3-600 and T3-400 corneal confocal microscopes, which have obtained the medical instruments registration certificate approved by the Jiangsu Provincial Pharmaceutical Administration. This corneal confocal microscope has achieved an industry breakthrough through technological innovation, becoming the first of its kind in the country to combine a wide field of view with high resolution. The device uses a laser light source and optical coherence tomography scanning technology, enhancing the scanning field to 600×600 μm with an optical resolution of 1.1 μm.
Gaush Meditech's Corneal Microscopes Achieve National Certification
Express News | Gaush Meditech - Corneal Confocal Microscopy Obtained National Medical Device Registration Certificate
Investors who bought high-level pharmaceutical Funds have hope! More than 80% of products achieved positive returns in the first quarter, and recovering losses is promising.
① A total of 264 medical Funds had positive returns in the first quarter of this year, accounting for over 80%, with many Funds achieving returns exceeding 15% this year. ② The net value of medical Funds established in 2020 and 2021 is currently being repaired, and investors who entered at high levels are expected to break even.
Gaush Meditech Ltd's (HKG:2407) 32% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/ERatio
Gaush Meditech Ltd Reports Revenue Growth but Declining Profits in 2024
There Are Reasons To Feel Uneasy About Gaush Meditech's (HKG:2407) Returns On Capital
